Amgen: MariTide's Progress, Reassessment Of The Horizon Acquisition
Summary
Amgen has not been a great performer in the last two years. Investors became and remain skeptical of MariTide's prospect...
Amgen has not been a great performer in the last two years. Investors became and remain skeptical of MariTide's prospects in obesity, type 2 diabetes, and other related indications. I continue to see MariTide's monthly dosing as a strong selling point and expect that addition of dose escalation to phase 3 trial design will improve its tolerability.